STU00097239: A Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for theTreatment of Lumbar Facet Syndrome

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT02478437
Collaborator
American Pain Society (Other)
48
1
2
38
1.3

Study Details

Study Description

Brief Summary

This study is being done to determine whether cooled radiofrequency ablation (CRFA) on the medial branch nerves of the lumbar facet joint is effective for the treatment of low back pain. CRFA blocks the nerves that carry pain signals from joints in the lower back such that the brain does not receive the message that the low back is in pain. This technique is commonly performed by burning these nerves rather freezing them, but it is suspected that freezing them results in better pain relief. The CRFA blocks has been shown to effectively treat sacroiliac joint pain (a joint in the pelvis), which is another reason that it is suspected that CRFA will be effective when treating pain related to facet joints in the low back. We are performing this study in order to determine if that is the case.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Conventional radiofrequency ablation (RFA)
  • Procedure: Cooled Radiofrequency Ablation (CRFA)
Phase 3

Detailed Description

The CRFA blocks has been shown to effectively treat sacroiliac joint pain (a joint in the pelvis), which is another reason that it is suspected that CRFA will be effective when treating pain related to facet joints in the low back. We are performing this study in order to determine if that is the case.

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for the Treatment of Lumbar Facet Syndrome
Study Start Date :
Jun 1, 2015
Actual Primary Completion Date :
Aug 1, 2018
Actual Study Completion Date :
Aug 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group 1

Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.

Procedure: Conventional radiofrequency ablation (RFA)
A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.

Active Comparator: Group 2

Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.

Procedure: Cooled Radiofrequency Ablation (CRFA)
Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.

Outcome Measures

Primary Outcome Measures

  1. Pain improvement [6 months post-procedure]

    Percent of participants who reported 50% or greater improvement in pain

Secondary Outcome Measures

  1. Global pain score [1 month, 3 months, 6 months and 12 months post procedure]

    Global Numeric Rating Scale (NRS, 0 is no pain and 10 is worst pain imaginable)

  2. McGill Pain Questionnaire (MPQ) [1 month, 3 months, 6 months and 12 months post procedure]

    Scores are tabulated by summing values associated with each word; scores range from 0 (no pain) to 78 (severe pain).

  3. Pain Anxiety Symptom Scale short form (PASS-20) [1 month, 3 months, 6 months and 12 months post procedure]

    The PASS-20 assesses 4 factorially distinct components of pain-related anxiety. Each question is in a form of a 6-point Likert Scale anchored from 0 (never) to 5 (always).

  4. Center for Epidemiologic Studies Depression short form index (CESD-10) [1 month, 3 months, 6 months and 12 months post procedure]

    The possible range of the 10-item scale is 0 to 30, and a cut off score of ten or higher indicates the presence of significant depressive symptoms. Subjects responded to each item of the scale by rating the frequency of each mood or symptom ''during the past week'' on a four-point scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with lumbar facet syndrome pain who would undergo treatment by lumbar medial branch radiofrequency ablation.

  • Low back pain for at least 6 months.

  • Pain resistant to conventional therapy including NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy or chiropractic care.

  • Pain diagram suggesting possibility of facet-mediated pain.

  • Referred pain when present not beyond the knee.

  • Positive response to at least 1 set of diagnostic intra-articular facet injections or medial branch blocks, defined as > 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine).

Exclusion Criteria:
  • Focal neurologic signs or symptoms.

  • Radiologic evidence of a symptomatic herniated disc or nerve root impingement related to spinal stenosis.

  • Previous radiofrequency ablation treatment for similar symptoms.

  • Patient refusal.

  • Lack of consent.

  • Active systemic or local infections at the site of proposed needle and electrode placement.

  • Coagulopathy or other bleeding disorder, current use of anticoagulants or anti-platelet medications.

  • Allergy to medications being used for injection procedures (contrast dye, local anesthetic, IV sedative).

  • Inability to read English, communicate with staff, or participate in follow up.

  • Pregnancy.

  • Cognitive deficit.

  • Negative response to diagnostic intra-articular facet injections or medial branch blocks, defined as < 75% reduction in pain following diagnostic blocks with local anesthetic (0.5mL of 0.5% bupivacaine OR 0.5 mL of 2% lidocaine).

  • Daily opiate analgesic use more exceeding 3 months prior to study inclusion.

  • Unstable medical or psychiatric illness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anesthesiology Pain Managment Center Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University
  • American Pain Society

Investigators

  • Principal Investigator: David Walega, MD, Northwestern University Feinberg School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
David Walega, Associate Professor, Chief, Division of Pain Medicine, Northwestern University
ClinicalTrials.gov Identifier:
NCT02478437
Other Study ID Numbers:
  • STU00097239
First Posted:
Jun 23, 2015
Last Update Posted:
Sep 6, 2018
Last Verified:
Sep 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by David Walega, Associate Professor, Chief, Division of Pain Medicine, Northwestern University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 6, 2018